Investigational gefurulimab met its primary efficacy endpoint in adults with anti-acetylcholine receptor (AChR) ...

The trial tested two doses of claseprubart -- 300 mg and 600 mg -- and its primary endpoint was safety. Secondary outcomes ...

DelveInsight’s Complement 3 Glomerulopathy Market Insights report includes a comprehensive understanding of current treatment practices, emerging complement 3 glomerulopathy drugs, market share of ...

When it comes to the English language, I'm confident no one meant to confuse us. There wasn't a panel of mean English teachers who sat around a table, finding ways to ...